NEW DELHI : The Drug Controller General of India (DCGI) has given approval to Hetero, a generic pharmaceutical company for manufacturing and marketing of the investigational antiviral medicine ‘Remdesivir’ from for the treatment of Covid-19.Hetero’s generic version of Remdesivir will be marketed under the brand name ‘COVIFOR’ in India.“In the light of increasing covid-19 cases in India, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes," Dr B Partha Saradhi Reddy, Chairman, Hetero Group of Companies said.“Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country.